Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1966 to 1980 of 9102 results

  1. Alectinib for treating unresectable locally advanced non-small-cell lung cancer [GID-TA12468]

    Awaiting development Reference number: GID-TA12468 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTG10173 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  3. Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]

    Awaiting development Reference number: GID-TA10791 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]

    Awaiting development Reference number: GID-TA11979 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    Awaiting development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

    Awaiting development Reference number: GID-TA11667 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]

    Awaiting development Reference number: GID-TA11874 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]

    In development Reference number: GID-TA11958 Expected publication date:  21 April 2027

    Technology appraisal guidance
    In development

  11. Clone of IPG190 Insertion of pleuro–amniotic shunt for fetal pleural effusion

    HealthTech guidance Reference number: HTG123 Published:  27 September 2006

    HealthTech guidance
    Awaiting development

  12. Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

    In development Reference number: GID-TA10249 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development Reference number: GID-TA10279 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development Reference number: GID-TA10748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development